Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1988/004205external-prioritypatent/WO1990005525A1/en
Application filed by PfizerfiledCriticalPfizer
Publication of BG51454A3publicationCriticalpatent/BG51454A3/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Nitrogen Condensed Heterocyclic Rings
(AREA)
Abstract
The method refers to the synthesis of a series of cis-3-//cyclic/methylamino-2-//α-substituted/arylmethyl/quinuclidines, 3-//cyclic/methylimino-2-//α-substituted/arylmethyl/quinuclidines, and cis-3-//cyclic/methyleneamino-2-//α-substituted/arylmethyl/quinuclidines, including their pharmaceutically acceptable salts. These derivatives are capable to act as substance P antagonists and may be used for treatment of gastrointestinal disorders, central nervous system disorders, inflammatory diseases, pain and migraine. The preferred derivatives are cis-3-//2-chlorophenyl/methylamino/-2-benzhydryl-quinuclidine, cis-3-//2- trifluorophenyl/methylamino/-2-benzhydryl-quinuclidine, and cis-3-//2-methoxyphenyl/methylamino/-2-benzhydryl-quinuclidine.
BG92491A1988-11-231990-07-20Method for preparating quinuclidine derivatives
BG51454A3
(en)
Use of nalmefene or naltrexone in the manufacture of a medicament for the treatment of inflammation in an arthritic disease or associated inflammatory diseases